SAN DIEGO, June 22, 2016 /PRNewswire/ -- Mirati
Therapeutics, Inc. (NASDAQ: MRTX) today announced that Mark Gergen will step down as Executive Vice
President and Chief Operations Officer to pursue other
opportunities, transitioning over the coming months.
"We want to thank Mark for his important contributions and
leadership over the past three years during a critical period for
the Company, and wish him all the best in his next endeavor," said
Charles M. Baum, M.D., Ph.D.,
president and CEO.
"We will continue to focus on our targeted oncology approach
with glesatinib and sitravatinib, where we have demonstrated clear
clinical benefit," continued Baum. "The remainder of 2016
will be dedicated to establishing clinical efficacy in these
programs."
As part of the transition, current Board chairman Rodney Lappe, Ph.D., will assume the role of
Executive Chairman, acting as an advisor to the management
team.
"We strongly believe in the Company and their scientific
approach to oncology and we fully support the management team as
they drive ongoing programs to critical clinical milestones in
2016," said Lappe.
About
Mirati
Mirati Therapeutics develops molecularly targeted therapies
intended to treat cancer by combining the three most important
factors in oncology drug development: 1) researching and developing
drug candidates that target genetic and epigenetic drivers of
cancer as single agents and in combination, including combination
with immune therapy, 2) designing creative and agile clinical
development strategies that select for patients whose tumors are
dependent on specific driver alterations, and 3) leveraging a
highly accomplished oncology precision medicine leadership team.
The Mirati team uses a blueprint proven by their prior work for
developing potential breakthrough cancer therapies with accelerated
development paths to improve outcomes for patients. Mirati is
advancing three drug candidates through clinical development for
multiple oncology indications. More information is available at
www.mirati.com.
Forward Looking Statements
Certain statements
contained in this news release, other than statements of fact that
are independently verifiable at the date hereof, contain
"forward-looking" statements, within the meaning of the Private
Securities Litigation Reform Act of 1995, that involve significant
risks and uncertainties. For more detailed disclosures and
discussions regarding such forward looking statements, please refer
to Mirati's filings with the U.S. Securities and Exchange
Commission ("SEC"), including without limitation Mirati's
filings on Forms 10-K, 10-Q, and 8-K. Forward looking
statements are based on the current expectations of management and
upon what management believes to be reasonable assumptions based on
information currently available to it. Such statements can
usually be identified by the use of words such as "may," "would,"
"believe," "intend," "plan," "anticipate," "estimate," "expect,"
and other similar terminology, or by statements that certain
actions, events or results "may" or "would" be taken, occur or be
achieved. Such statements include, but are not limited to,
statements regarding Mirati's development plans and timelines,
potential regulatory actions, expected use of cash resources, the
timing and results of clinical trials, and the potential benefits
of and markets for Mirati's product candidates. Forward
looking statements involve significant risks and uncertainties and
are neither a prediction nor a guarantee that future events or
circumstances will occur. Such risks include, but are not
limited to, potential delays in development timelines or negative
clinical trial results, reliance on third parties for development
efforts, changes in the competitive landscape, changes in the
standard of care, as well as other risks described in Mirati's
filings with the SEC. We are including this cautionary note to
make applicable, and to take advantage of, the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995
for forward-looking statements. The information in this news
release is given as of the date above and Mirati expressly
disclaims any obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise, unless required by law.
Logo - http://photos.prnewswire.com/prnh/20160307/341355LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/mirati-therapeutics-announces-change-in-executive-leadership-300288863.html
SOURCE Mirati Therapeutics, Inc.